MINNEAPOLIS, Aug. 10, 2017 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB:SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, today provides a clinical update and reports financial results for the second quarter ending June 30, 2017.
